NCT07129993 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07129993
Title	Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Daiichi Sankyo
Indications	bladder urothelial carcinoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma urethra transitional cell carcinoma
Therapies	Cisplatin + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan Cisplatin + Gemcitabine Carboplatin + Gemcitabine
Age Groups:	adult \| senior
Covered Countries	USA \| FRA

No variant requirements are available.